TP53 ‐Mutated Myeloid Neoplasms: 2024 Update on Diagnosis, Risk‐Stratification, and Management
American Journal of Hematology · 2025-06 · 100 (S4) · 88-115
DOI: 10.1002/ajh.27655 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift American Journal of Hematology, online erschienen am 11.03.2025. Verfasst von Mithun Vinod Shah und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA. Hauptthemen laut MEDLINE: Tumor Suppressor Protein p53, Mutation, Leukemia, Myeloid, Acute, Myelodysplastic Syndromes. Die Arbeit wurde bisher 43-mal zitiert (Crossref) und nennt 159 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Astellas Pharma, AbbVie, KURA Oncology, Inc..
Abstract (Originalsprache)
Alterations in the tumor suppressor gene TP53 are common in human cancers and are associated with an aggressive nature. Approximately 8%–12% of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) harbor TP53 mutations ( TP53 mut ) and present immense challenges due to inherent chemoresistance and poor outcomes. As TP53 mut are more common in older individuals and those with secondary/therapy‐related myeloid neoplasms (MN), their incidence is expected to increase with an aging population and rising proportion of cancer survivors. Treatments used for other MN—intensive chemotherapy, hypomethylating agents, and the BCL‐2 inhibitor venetoclax—do not improve the survival of TP53 mut MN patients meaningfully. Additionally, further development of many promising agents has been discontinued, highlighting the challenges. Widespread acknowledgment of these problems led to the recognition of TP53 mut MN as a distinct entity in the 5th edition of the World Health Organization and International Consensus Classifications. However, critical discrepancies between the two classifications may lead to under‐ or overestimation of the prognostic risk. Here, we review recent advances in the biology, diagnosis, and treatment of TP53 mut MN. The development of TP53 mut MN is positioned at the intersection of age, hereditary predisposition, and anti‐cancer therapies. Precursor TP53 mut clones can be detected years prior to the eventual leukemic transformation—raising the possibility of early intervention. We discuss the two classification systems and the bearing of the discrepancies between the two on timely and effective management. We provide novel evidence in the areas of discrepancies. Finally, we review the current therapeutic landscape and the obvious limitations of the currently used therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA.
- Department of Pathology, University of Chicago, Chicago, Illinois, USA.
- Department of Haematology, Royal Adelaide Hospital, Central Adelaide Local Health Network, Adelaide, South Australia, Australia.
- Precision Medicine Theme, South Australian Health and Medical Research Institute (SAHMRI), Adelaide, South Australia, Australia.
- Adelaide Medical School, University of Adelaide, Adelaide, South Australia, Australia.
ORCID-Profile: Mithun Vinod Shah, Daniel A Arber, Devendra K Hiwase
Förderung
- Astellas Pharma
- AbbVie
- KURA Oncology, Inc.
- Bristol Myers Squibb/Celgene
- Marker Therapeutics
- AbbVie Canada
- Celgene
Zitieren
APA
Shah, M. V., Arber, D. A., & Hiwase, D. K. (2025). TP53 ‐Mutated Myeloid Neoplasms: 2024 Update on Diagnosis, Risk‐Stratification, and Management. American Journal of Hematology, 100(S4), 88-115. https://doi.org/10.1002/ajh.27655
Vancouver
Shah MV, Arber DA, Hiwase DK. TP53 ‐Mutated Myeloid Neoplasms: 2024 Update on Diagnosis, Risk‐Stratification, and Management. American Journal of Hematology. 2025;100(S4):88-115. doi:10.1002/ajh.27655
BibTeX
@article{Shah2025,
author = {Shah, Mithun Vinod and Arber, Daniel A and Hiwase, Devendra K},
title = {TP53 ‐Mutated Myeloid Neoplasms: 2024 Update on Diagnosis, Risk‐Stratification, and Management},
journal = {American Journal of Hematology},
year = {2025},
volume = {100},
number = {S4},
pages = {88--115},
doi = {10.1002/ajh.27655}
}
EUVIMED